The ongoing legal battle over Mifepristone, an abortion pill widely used in the United States, has reignited discussions around abortion rights. Recently, the U.S. Supreme Court allowed the continued prescription of Mifepristone via telemedicine, temporarily halting a lower court ruling that could have restricted access. This case emerged after Louisiana challenged the U.S. Food and Drug Administration's (FDA) approval for mail-order prescriptions, arguing that it weakened state abortion laws and posed safety risks. Approved by the FDA in 2000, Mifepristone is typically used in combination with Misoprostol to terminate pregnancies during the first 10 weeks. Medical organizations, including the American Medical Association, support its safety, noting that serious complications are rare. As medication abortions have become the most common form of abortion care in the U.S., the ongoing legal disputes over Mifepristone reflect the heightened political tensions following the Supreme Court's 2022 decision to overturn Roe v. Wade. While Mifepristone remains accessible for now, alternatives like Misoprostol exist, albeit with some limitations. The future of Mifepristone continues to be a contentious issue in the national debate on reproductive healthcare.